Metabolic
CAS
2023788-19-2
Molecular Weight
4813
Da
A once-weekly injectable dual hormone receptor agonist targeting both GIP and GLP-1 receptors simultaneously, making it the most clinically proven weight loss medication currently available by prescription. FDA approved in May 2022 under the brand name Mounjaro for type 2 diabetes and in November 2023 as Zepbound for chronic weight management. The SURMOUNT clinical trial program — one of the largest obesity drug trial programs ever conducted — demonstrated up to 20.9% body weight loss at the highest dose over 72 weeks, outcomes previously associated only with bariatric surgery. Requires a prescription through a licensed provider.
Injectable
Intranasal Suitable
No
Prescription
Community enthusiasm runs slightly higher than semaglutide, largely because weight loss outcomes reported anecdotally tend to exceed GLP-1 monotherapy results. r/Tirzepatide is an active community with granular week-by-week progress logs from users. Appetite suppression is described as more complete than semaglutide by users who have tried both. GI side effects are reported as more manageable than semaglutide at equivalent weight loss outcomes, a pattern that aligns with trial data. Cost and access dominate community discussion, branded Zepbound pricing is frequently compared against compounded alternatives. Muscle retention with adequate protein intake is a recurring topic in more sophisticated threads.
We break down one compound like this every week
The Honest Dose — free, no sponsorships, no agenda. Just the evidence.
Tirzepatide is a synthetic peptide engineered from the native GIP hormone sequence with modifications enabling dual agonism at both GIP and GLP-1 receptors. Developed by Eli Lilly and Company, it represents the next generation of incretin-based therapy following the success of GLP-1 mono-agonists like semaglutide. Its fatty acid side chain binds albumin in the bloodstream, similar to the DAC mechanism in CJC-1295, dramatically extending its half-life to approximately 5 days and enabling once-weekly dosing. It is the direct predecessor compound to Retatrutide, which adds a third glucagon receptor to tirzepatide's dual mechanism. The brand name Mounjaro is used for the diabetes indication while Zepbound is the obesity-specific formulation, they contain the same active ingredient at the same doses.
Tirzepatide activates GIP receptors and GLP-1 receptors through a unique dual agonism mechanism. GLP-1 receptor activation stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon, slows gastric emptying, and reduces appetite through central nervous system signaling. GIP receptor activation works synergistically, enhancing insulin secretion, improving insulin sensitivity in adipose tissue, and amplifying the weight loss effect beyond what GLP-1 mono-agonism achieves alone. The dual mechanism appears to produce greater weight reduction than either pathway targeted individually, as demonstrated by head-to-head data against semaglutide in the SURPASS-2 trial. Its affinity for GIP receptors matches that of native GIP while its GLP-1 receptor affinity is approximately five times weaker than native GLP-1, a deliberate design choice that balances efficacy with tolerability.
Tirzepatide has the most robust human evidence base of any compound in the Metabolic category on PeptideClear. The SURMOUNT clinical trial program evaluated tirzepatide across thousands of participants with obesity and overweight, with and without type 2 diabetes.
In the landmark SURMOUNT-1 trial, mean percentage weight change at 72 weeks was -15.0% at 5mg, -19.5% at 10mg, and -20.9% at 15mg weekly doses compared to -3.1% in the placebo group. These outcomes represent a meaningful advance over older approved obesity medications which typically produce 3-8.6% placebo-adjusted weight reduction.
Beyond weight loss, tirzepatide has demonstrated clinically meaningful improvements across a range of obesity-related complications including sleep apnea reduction, improvements in metabolic-dysfunction associated steatohepatitis (MASH), heart failure outcomes, and cardiovascular risk reduction. The SURMOUNT-OSA and SUMMIT trials extended the evidence base into these complication-specific indications.
For type 2 diabetes, the SURPASS program demonstrated superior HbA1c reductions compared to GLP-1 receptor agonists including semaglutide. Tirzepatide is appropriate for adults with obesity or overweight with at least one weight-related condition, and for adults with type 2 diabetes requiring additional glycemic control.
The safety profile of tirzepatide is well characterized across thousands of trial participants and mirrors that of GLP-1 receptor agonists. The most common adverse effects are gastrointestinal, nausea affects approximately three times more tirzepatide users than placebo, vomiting approximately six times more, and diarrhea approximately three times more. These effects are typically dose-dependent and most pronounced during dose escalation, often resolving with time. Serious but rare risks include pancreatitis, gallbladder disease, and a theoretical risk of thyroid C-cell tumors identified in rodent studies, though this has not been confirmed in humans. Not recommended during pregnancy. Requires ongoing provider supervision and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2. Rebound weight gain upon discontinuation is well documented and represents a significant consideration for long-term use planning.
Available as a once-weekly subcutaneous auto-injector pen in doses of 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg. Standard practice is to initiate at 2.5mg weekly for 4 weeks and escalate by 2.5mg increments every 4 weeks as tolerated to a target maintenance dose. Injected subcutaneously into the abdomen, thigh, or upper arm. Requires refrigeration. Prescription only, available through licensed pharmacies and covered by many insurance plans for qualifying diagnoses.
FDA approved May 2022 (Mounjaro) for type 2 diabetes management. FDA approved November 2023 (Zepbound) for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition. Also approved in the European Union, United Kingdom, Japan, and numerous other markets. Prescription only, requires a licensed provider. Available through standard pharmacy channels and increasingly through telehealth weight management programs.
https://pubmed.ncbi.nlm.nih.gov/39536238/
https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
https://pubmed.ncbi.nlm.nih.gov/34170647/
https://pubmed.ncbi.nlm.nih.gov/37385275/
https://pubmed.ncbi.nlm.nih.gov/37840095/
Retatrutide, GLP-1, Tesamorelin, AOD-9604
Enjoyed this profile? Get one compound broken down in depth every week in The Honest Dose.
Join The Honest Dose →Last Reviewed